Skip to content

Impact of dementia-related neurodegeneration on pain processing

Impact of dementia-related neurodegeneration on pain processing - Pain processing in dementia

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON47032
Enrollment
125
Registered
2018-03-16
Start date
2016-11-25
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer desease dementia

Interventions

dementia
neurodegeneration
pain

Sponsors

Huisartsgeneeskunde
Lead Sponsor

Eligibility

Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: In order to be eligible to participate in this study, a subject must meet all of the following criteria:;All subjects: - Age from 55 * 85 yr - Willingness to cooperate and sign written informed consent * or proxy consent with assent of participating subject;Normal Healthy Controls (CP): - MMSE scores between 27-30 - Without subjective memory complaints;Alzheimers*s disease dementia (AD): - Diagnosis of probable AD according to the Alzheimer*s disease and Related Disorders Associations (NINCDS-ADRDA) criteria and NIA-AA guidelines ( McKhann et al. 2011).;Frontotemporal dementia (FTD): - Diagnosis of behavioral variant FTD (FTD-b) according to the revised consensus criteria (Rascovsky et al. 2011). - Diagnosis of a subtype of FTD of Primary Progressive Aphasia (PPA), divided into Semantic Dementia (SD), Progressive Nonfluent Aphasia (PNFA) and LPA due to FTD (Gorno-Tempini et al. 2011). ;Vascular dementia (VD): - Diagnosis of probable VD according to the NINDS-AIREN (National Institute of Neurological Disorders and Stroke and the Association Internationale pour la Recherche et l*Enseignement en Neurosciences) guidelines (Roman et al. 1993).

Exclusion criteria

Exclusion criteria: All subjects: - History of major psychiatric illness - Medications which may affect pain processing (selective serotonin re-uptake inhibitors, opioids, other analgesics) - Contraindications for MR-measurements (e.g. cochlear implants and most permanent pacemakers, red tattoos);Normal healthy Controls: - abnormal results on neuropsychological tests - subjective memory complaints;All patients: - Cognitive deficits could be explained by non-neurodegenerative condition (e.g. stroke, neoplasm, head injury, hydrocephalus or other medical condition)

Design outcomes

Primary

MeasureTime frame
Response to various mild pain stimuli (pressure pain will be applied to the shoulder and temperature (heat) will be applied to the forearm ) - Self -report - Facial expression (the face will be videotaped and analyzed using the Facial Action Coding System) - Heartrate and heartrate-variability

Secondary

MeasureTime frame
- structural MRI (grey and white matter (especially in frontal areas)) - Neuropsychology testing (attention, memory, executive functioning)

Countries

The Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)